Published Manuscripts (2015)

Skovgaard R, Jon Ploug U, Hunt B, Valentine WJ. Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. Clinical Therapeutics 2015; 37(8): 1677-88.

Muduma G, Odeyemi I, Pollock RF. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK. Journal of Medical Economics 2015; 18(12): 1050-9.

Muratalina A, Smith-Palmer J, Nurbekova A, Abduakhassova G, Zhubandykova L, Roze S, Karamalis M, Shamshatova G, Demessinov A, Dunne D’Agostino N, Lynch P, Larisa Yedigarova L, Klots M, Valentine W, Welsh J, Kaufman F. Project Baiterek: a patient access program to improve clinical outcomes and quality of life in children with type 1 diabetes in Kazakhstan. Value in Health Regional Issues 2015; 7: 74-9.

Roze S, Smith-Palmer J, Valentine W, de Portu S, Nørgaard K, Pickup JC. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in type 1 diabetes: a systematic review. Diabetic Medicine 2015; 32(11): 1415-24.

Smith-Palmer J, Boye KS, Perez-Nieves M, Valentine W, Bae JP. Cardiovascular risk profiles in Type 2 diabetes and the impact of geographical setting. Expert Review of Endocrinology & Metabolism 2015; 10: 243–57.

Goh SY, Tan SC, Lim LC, Chua B, Hunt B. Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore. Journal of Diabetology 2015; 1:2.

Hunt B, Aguilar Garza JL, Enríquez Vázquez CJ, Jain P, Valentine WJ. Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. Value in Health Regional Issues 2015; 8c: 20-7.

Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Research and Clinical Practice 2015; 109(1): 95-103.

Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes. Diabetic Medicine 2015; 32(5): 618-26.

Pollock RF, Kappelgaard AM, Seitz L. An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opinion on Drug Delivery 2015; 12(3): 353-60.

Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. Diabetes Therapy 2015; 6(1): 61-74.

Bargalló-Rocha JE, Lara-Medina F, Pérez-Sánchez V, Vázquez-Romo R, Villarreal-Garza C, Martínez-Said H, Shaw-Dulin RJ, Mohar-Betancourt A, Hunt B, Plun-Favreau J, Valentine WJ. Cost-effectiveness of the 21-gene breast cancer assay in Mexico. Advances in Therapy 2015; 32(3): 239-53.

Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases 2015; 15(1): 19.